TRAP220 inhibitors belong to a distinctive chemical class of compounds that have garnered significant attention within the realm of molecular research. These inhibitors specifically target the Transcriptional Adaptor 220 (TRAP220) protein, a crucial component of various transcriptional complexes responsible for regulating gene expression. TRAP220, also known as PPARBP or MED1, serves as a coactivator in transcriptional processes, facilitating the interaction between transcription factors and the RNA polymerase II complex. It plays a pivotal role in gene transcription related to a wide array of cellular functions, including development, metabolism, and cell differentiation.
TRAP220 inhibitors are meticulously designed molecules that function by impeding the interaction between TRAP220 and its binding partners, thereby hindering the coactivation of gene transcription. These inhibitors act as potent modulators of gene expression, allowing researchers to delve deeper into the intricate mechanisms underlying various biological processes. By selectively targeting the TRAP220 protein, these inhibitors offer a valuable tool for deciphering the complexities of transcriptional regulation and its impact on cellular functions. Moreover, the development of TRAP220 inhibitors opens up new avenues for exploring applications in molecular biology research and enhancing our understanding of gene expression networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity, disrupting downstream signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets and inhibits BCR-ABL tyrosine kinase, used for chronic myeloid leukemia (CML) and other cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multikinase inhibitor; interrupts RAF/MEK/ERK signaling and VEGFR/PDGFR tyrosine kinases in cancer cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual HER2 and EGFR inhibitor, hindering cell growth and proliferation in HER2-positive breast cancer. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets multiple tyrosine kinases including BCR-ABL, SRC family kinases; used in CML and acute lymphoblastic leukemia. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically inhibits mutated BRAF kinase in melanomas with the V600E mutation, attenuating MAPK pathway activation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Blocks CDK4/6, halting cell cycle progression, and used in combination with endocrine therapy in hormone receptor-positive breast cancer. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Selective JAK1/JAK2 inhibitor; modulates cytokine signaling and used for myelofibrosis and polycythemia vera. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Targets ALK kinase and inhibits ALK-dependent tumor growth, approved for ALK-positive non-small cell lung cancer. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK, a key mediator in B-cell signaling; used for B-cell malignancies like CLL and lymphomas. | ||||||